# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

> **NCT06754605** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sinocelltech Ltd.** · enrollment: 480 (estimated)

## Conditions studied

- Respiratory Syncytial Virus

## Interventions

- **BIOLOGICAL:** SCTV02
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT06754605
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2027-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2025-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754605, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06754605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*